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 ABSTRACT
Kidney transplantation is the optimal treatment of end -stage renal disease (ESRD) improving survival 
and quality of life for most recipients. In our country, potential living donors have been refused due to the 
ABO incompatibility barrier. However, ABO -incompatible living donor kidney transplant is presently common 
practice in several countries with good outcomes.
The authors describe a case of a 49 -year -old female patient, with chronic kidney disease due to autosomal 
dominant polycystic kidney disease, who had started haemodialysis 10 months before and with blood group 
O. The living donor was a 53 -year -old sister with blood group B. The desensitization protocol was based 
on rituximab and plasmapheresis. The induction protocol used was basiliximab, tacrolimus, mofetil myco-
phenolate and metilprednisolone. Five days post -transplant she presented a normal graft function that 
remained during the eight months follow -up. This case reveals the first ABO incompatible living donor 
kidney transplant performed in Portugal with excellent outcome.
Key -Words: ABO -incompatibility; kidney transplantation; living donor.
 RESUMO
O transplante renal é a modalidade de tratamento da doença renal crónica estadio 5 associada a mel-
hores sobrevivência e qualidade de vida. No nosso país muitos potenciais dadores vivos têm sido recusados 
devido à incompatibilidade ABO. Contudo, o transplante renal de dador vivo ABO incompatível é hoje 
prática comum em diversos países com resultados positivos. Os autores descrevem o caso de doente do 
sexo feminino, de 49 anos, com doença renal crónica secundária a doença renal poliquística autossómica 
dominante, que havia iniciado hemodiálise 10 meses antes e com grupo sanguíneo O. O dador vivo foi 
uma irmã de 53 anos, grupo sanguíneo B. O protocolo de dessensibilização baseou -se em rituximab e 
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 INTRODUCTION
Kidney transplantation is the optimal treatment 
of end -stage renal disease (ESRD) improving sur-
vival and quality of life for most recipients1. How-
ever, nowadays, the waiting list for deceased donor 
transplantation continues to grow2 due to increas-
ing prevalence of ESRD worldwide whereat demand 
for kidneys far exceeds the available supply3. 
Patients with ESRD who receive a kidney transplant 
are associated with a reduced risk of mortality 
compared with patients who remain on the waiting 
list4. A longer time on dialysis is responsible for 
inferior health status and greater exposure risk to 
sensitizing events resulting in higher sensitization 
to human leukocyte antigens at the time of trans-
plantation5,6. This leads to inferior long -term out-
comes after transplantation7,8. Longer waiting 
times are not only associated with higher waiting 
list mortality and morbidity, but may also lead to 
inferior outcomes after transplantation9,10. Waiting 
time has been shown as the strongest modifiable 
risk factor for the outcome after kidney transplan-
tation7,8. Blood group O recipients have signifi-
cantly longer time on dialysis than patients from 
other blood groups8. A previous study11 reported 
for deceased donor kidney transplant (DDKT) 
median times on dialysis of 77 months for blood 
group O recipients versus 21 -42,5 months for other 
blood group recipients in the north of Portugal, 
in 2011.
Living donor kidney transplant (LDKT) allows not 
only superior outcomes in terms of both graft and 
patient survival12 but also an earlier transplantation, 
which is associated with better outcomes. Neverthe-
less, this practice has been precluded in Portugal 
by ABO -incompatibility barrier and represents the 
reason for refusal of 20 -25% of the potential living 
donors.
Patients with blood group O have disadvantages 
in the allocation of deceased donor organs in the 
Eurotransplant Kidney Allocation System and fewer 
ABO -compatible living donors8.
ABO -incompatible (ABOi) LDKT is currently com-
mon practice in several European countries, Australia, 
Japan and United States with promising outcomes 
and is the alternative for kidney paired donation 
programmes13 which have their efficacy compromised 
due to blood group O recipients saturation.
 CASE REPORT
We report a case of a 49 -year -old Caucasian 
autonomous woman that started haemodialysis, in 
January 2014, due to chronic kidney disease second-
ary to autosomal dominant polycystic kidney disease. 
The patient´s personal history included two term 
pregnancies, and right nephrectomy, in March 2014, 
complicated with upper gastrointestinal bleeding that 
required four blood transfusions.
On the 10th November 2014, she was admitted to 
ABOi LDKT preparation. Four potential living donors 
were evaluated and the choice fell on the one who 
caused the lowest ABO -antibody titre in the recipient. 
The living donor was a 53 -year -old sister with blood 
group B, haploidentical.
The recipient had blood group O, a panel reactive 
antibody (PRA) of 0%, negative CDC crossmatch for 
B and T lymphocytes. Flow cytometry crossmatch 
was positive for B lymphocytes and negative for T 
lymphocytes. Anti -HLA alloantibody class I and class 
II research with luminex was negative.
Pre -treatment anti -B IgG titre was 1/128.
plasmaferese. O protocolo de indução foi com basiliximab, tacrolimus, micofenolato de mofetil e metilpred-
nisolona. Evoluiu com função normal do enxerto 5 dias pós -transplante que se manteve durante o follow -up 
de 8 meses. Este caso clinico ilustra o primeiro transplante renal de dador vivo ABO incompatível efectuado 
em Portugal com excelente resultado.
Palavras -Chave: Dador vivo; incompatibilidade ABO; transplantação renal.
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A desensitization protocol was begun on 11th Novem-
ber 2014 with rituximab (in a single dose of 375mg/
m2). Seven plasmapheresis (PF) sessions were per-
formed until reaching the target titre of anti -B IgG of 
1/8. The induction protocol used was basiliximab, tacro-
limus, mofetil mycophenolate and metilprednisolone.
Kidney transplantation was performed on 20th 
November 2014. The surgical procedure elapsed with-
out problems and immediate diuresis presented.
Post -transplant PF sessions were performed 
according with anti -B IgG titres taking into account 
the target that in the first week post -transplant was 
≤ 1/8 and in the second week post -transplant was 
≤ 1/16. From the second week on there were no more 
anti -B IgG titres target. This patient in the first week 
performed daily PF sessions (6 sessions) and in the 
second week reduced PF sessions frequency (per-
formed only 2 sessions). After each PF session anti-
-cytomegalovirus specific immunoglobulin (100mg/
Kg) was administered, except on the session of 28th 
November when a single administration of non-
-specific human intravenous immunoglobulin (IVIG) 
(0.3mg/Kg) was made.
Serum creatinine (SCr) decreased progressively 
and on the 5th day post -transplant presented a nor-
mal graft function.
Eight months post -transplant the patients remained 
with normal graft function (SCr 1.2 mg/dL) and with 
anti -B IgG titer of 1/8.
 DISCUSSION
The ABO -incompatibility was absolute contraindica-
tion for kidney transplantation until the 1980s. Owing 
to the shortage of deceased donors in Japan due to 
lack of brain death legislation, since 1989, ABOi LDKT 
has been performed to expand the indication for 
LDKT and during the past two decades about 2,000 
ABOi LDKTs were performed14. There was an impres-
sive improvement in the success rate for those kidney 
transplants and, since 2001, the outcomes are similar 
to those obtained in ABO -compatible LDKT.
Anti -A/anti -B antibodies that elicit antibody-
-mediated rejection (AMR) are not only natural/
preformed antibodies that generally may cause hyper-
acute rejection, but also de novo antibodies that are 
produced after transplantation, as a result of stimula-
tion and sensitization by the ABO -histo group antigens 
present on the surface of the vascular endothelial 
cells in the graft and that cause acute AMR. It has 
been observed that the de novo antibodies are the 
most pathogenic. This fact has extremely important 
implications for therapeutic strategy in ABOi organ 
transplantation. Thus, the most important treatment 
step for ensuring a successful graft outcome is desen-
sitization therapy mainly based on pre - and post-
-transplant antibody removal (plasmapheresis and 
immunoabsorption). Actually, the pre -transplant sup-
pression of host B cell immunity with rituximab is 
considered an adjunctive therapy that performs a 
partial pharmacologic splenectomy and obviates surgi-
cal risks of splenectomy15. The newly described ABOi 
desensitization protocols advogate avoidance of a 
surgical splenectomy15. The utility of routine rituximab 
administration remains uncertain. Despite an absence 
of detectable B cells after rituximab administration, 
plasma cells lack CD 20 receptors and are able to 
produce isoagglutinin antibodies. The depletion of 
plasma cell precursors only decrease the risk of AMR 
if used in conjunction with other antibody -depleting 
measures. There are some reports that suggest that 
attention to the isoagglutinin titre at the time of trans-
plantation and routine post -transplant antibody reduc-
tion with either plasmapheresis or immunoadsorption 
may significantly reduce the risk of AMR and allow 
for the elimination of splenectomy and rituximab from 
the ABOi desensitization protocol16,17.
Acute AMR tends to occur especially within 2 to 
7 days post -transplant14. The incidence decreases 
after this period, and instances of acute AMR occur-
ring more than 1 month post -transplant were not 
found. This dangerous period is called “critical period” 
(Figure 1). It is preceded by the “silent period” that 
consists in the first 2 days post -transplantation once 
AMR due to ABO histo -blood group antigens does 
not arise. Accommodation was established 1 to 2 
weeks post -transplant in many cases. Once accom-
modation has been established, there are no further 
instances of acute AMR throughout the graft´s life. 
This period is called “stable period”.
The accommodation phenomenon is defined as 
the situation in which, although the vascular endo-
thelial cells in the graft carry ABO histo -blood 
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antigens on their surface and the blood of the recipi-
ents contains antibodies to those antigens, no 
antigen -antibody reaction occurs, and there is no 
occurrence of acute AMR. In vitro studies demon-
strated that the binding of anti -A/B antibodies to 
human endothelial cells led to up -regulation of 
complement inhibitors, such as CD55 and CD59 and 
other graft -protecting genes, thereby leading to resis-
tance to complement -dependent cytotoxicity18.
The study by Montgomery et al.13 showed that 
long -term patient survival was not significantly dif-
ferent between the cohorts of ABOi recipients and 
ABO compatible recipients. However, graft loss was 
significantly higher, particularly in the first 14 days 
post -transplant, with little -to -no difference beyond 
day 14. Graft loss in the first 14 days post -transplant 
was greater in patients with also pre -transplant donor 
specific antibodies.
Nevertheless, Fehr and Stussi´s review article18 
reported that short -term results of ABOi kidney trans-
plantation, in terms of patient and graft survival, are 
excellent in all reported series worldwide and, alto-
gether, it seems that ABOi kidney transplantation is 
well tolerated and has comparable outcomes to ABO-
-compatible transplantation. These results have been 
achieved with desensitization strategies based on 
antibody removal techniques (standard PF, double 
filtration PF, immunoadsorption) and on intensified 
immunosuppression protocols (inclusively using ritux-
imab as an element of B -cell depletion). For main-
tenance immunosuppression there are no randomized 
trials available. Most groups performing ABOi kidney 
transplantation nowadays use the regimen based on 
tacrolimus, mycophenolate, and corticosteroids.
Desensitization regimens pretransplant and post-
-transplant used in the several studies were different, 
but all of them obtained good outcomes13,19 -22.
Recently, in 2015, Opelz et al.23 reported outcomes 
of 1420 ABOi LDKT performed after ABO -antibody 
reduction in European patients. Once again was con-
cluded that death -censored graft and patient survival 
rates in ABOi LDKT were similar to those achieved 
in ABO -compatible control groups.
In 2008, Tobian et al.24 have already reported 
that higher anti -A/ -B IgG baseline titres would require 
more PF sessions and established guidelines about 
the number of pre -transplant and post -transplant 
PF sessions according to ABO antibody baseline 
titre. Later, in 2011, Lawrence et al.25 suggested 
that there is an exponential relationship between 
IgG titre and the number of PF sessions required to 
reach the target titre. This allows not only to predict 
with a reasonable degree of accuracy, from the base-
line titre, how many PF sessions are likely to be 
required, but also to predict which patients should 
not enter the ABOi programme. As transplantation 
is only achieved in 33.3% of patients with anti -ABO 
titres ≥1:512, but 95.6% of patients with titres ≤1:256, 
shall only be accepted patients for ABOi kidney 
transplantation with IgG titre ≤1:256. Nowadays, it 
is not known at what titre it is prudent to proceed 
to transplantation and the cut -off titre for transplan-
tation is between 1:4 and 1:32, depending on centre 
practice.
Our first ABOi LDKT in Portugal was performed 
based in the previous experience worldwide reported 
in the mentioned trials.
Figure 1
Onset of acute antibody -mediated rejection.
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The positive flow cytometry crossmatch for B lym-
phocytes was interpreted in the context of ABO 
incompatibility. Furthermore, there were no present 
donor specific antibodies.
We used a desensitization protocol based on PF 
and rituximab. However, recent reports23,26 showed 
that a rituximab free ABOi protocol yields similar 
excellent short - and long -term results after kidney 
transplantation. Maybe in the future we will perform 
ABOi LDKT with a lower dose of rituximab or without 
it. This is of considerable interest in order to reduce 
the high risk of infection and other complications 
associated with desensitization and intensified immu-
nosuppression required for ABOi LDKT.
The outcomes were favourable and similar to those 
described in the literature (Table I).
 CONCLUSION
This case reveals the first ABOi LDKT performed 
in Portugal with excellent outcome, representing a 
stimulus to the disclosure of this technique.
The encouraging results obtained worldwide and 
the advantages of ABOi LDKT, especially for blood 
group O ESRD patients, must be considered in order 
to expand this kind of kidney transplantation.
The ABOi LDKT programme shall not be faced as 
a substitute but as complementary to paired dona-
tion programmes that give answer to the patients 
with ABO antibody titres > 1:256. On the other hand, 
the ABOi LDKT programme consists in an alternative 
option for blood group O recipients with long time 
on dialysis due to blood group O saturation in those 
paired donation programmes.
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